Benign Prostatic Hypertrophy Clinical Trial
Spinal block is the most common anesthetic technique for transurethral resection of
prostatectomy (TURP). Most patients undergoing TURP are elderly and frequently present with
cardiopulmonary and endocrine diseases. Low-dose local anesthetic is commonly administer to
limit the block level to minimize the hemodynamic changes. However, sometimes it may not
provide an adequate level of sensory block. Thus, intrathecal additive is frequently
administer with local anesthetic to improve analgesic effect.
Dexmedetomidine(DXM), a selective 2-adrenoreceptor agonist, has been used in the epidural
space in humans without any reports of neurological deficits. Previous clinical studies
showed that intravenous dexmedetomidine administration prolonged the sensory and motor
blocks of bupivacaine spinal analgesia. But clinical studies about the use of intrathecal
DXM with local anesthesia in humans are scarce in the literature. Kanazi et al. found that
3μg DXM added to 12 mg spinal bupivacaine produced the significant short onset of sensory
and motor block as well as significantly longer duration of sensory and motor block than
bupivacaine. And Al-Mustafa et al. reported that intrathecal dexmedetomidine as an adjuvant
to 12.5mg bupivacaine in spinal anesthesia has a dose dependant effect on the onset and
regression of sensory and motor block.
In our previous study, low-dose diluted bupivacaine 5 mg provided sufficient anesthetic
level when opioid was added with local anesthetic. However, opioid-induced side effects,
such as pruritus, nausea, or vomiting, could be an obstacle in common use. The aim of this
study is to evaluate whether DXM-low-dose bupivacaine spinal anesthesia can provide the
effective spinal anesthesia and postoperative analgesia with minimal side effect compare to
the local anesthetic only group.
This study was conducted in a randomized, double-blind, controlled fashion. Patients were
randomly allocated to DXM group or Saline group. DMT group received hyperbaric bupivacaine
0.5% (1.2 ml) (6 mg) in dextrose 8% solution + DMT 0.3 ml (3 µg)-in total, bupivacaine 0.4%
(1.5 ml) intrathecally and Saline group received hyperbaric bupivacaine 0.5% (1.2 ml) (6 mg)
in dextrose 8% solution + normal saline 0.3 ml -in total, bupivacaine 0.4% (1.5 ml)
intrathecally. After spinal block, the level of sensory block, defined as the dermatomal
segment with loss of pain sensation to pin-prick with a 22 G hypodermic needle and cold
sensation to alcohol swab was measured every 2 min after intrathecal injection. The
investigators recorded the peak sensory block level, time to peak block level from
intrathecal injection, blood pressure and heart rate, and analgesic supplementation during
operation. The maximum motor block level was assessed according to the modified Bromage
scale. During postoperative period, the frequency of analgesic requirement, time to the
first analgesic request, and pain scores were evaluated by blind investigator.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02509975 -
Safety and Efficacy of OCL 503 in Prostate Artery Embolization
|
N/A | |
Completed |
NCT01177436 -
Prostate Cancer Antigen 3 (PCA-3) Gene Project
|
N/A | |
Completed |
NCT05082142 -
Tranexamic Acid to Improve Same-day Discharge Rates After Holmium Laser Enucleation of the Prostate (HoLEP)
|
Phase 4 | |
Completed |
NCT01260129 -
Safety and Efficacy of QD Versus BID Silodosin With Lower Urinary Tract Symptoms Suggestive of BPH
|
Phase 4 | |
Completed |
NCT00771394 -
Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia
|
Phase 4 | |
Active, not recruiting |
NCT03630926 -
Evaluation of the NV-VPAC1 Prostate Cancer (PCa) Urine Diagnostic Test in Subjects With Biopsy-confirmed Prostate Cancer, Benign Prostatic Hypertrophy, or Bladder/Kidney Stones.
|
||
Completed |
NCT02429219 -
Saline With Alcohol in TransUrethral Resection aNd Photoselective Vaporisation of the Prostate
|
N/A | |
Completed |
NCT00382356 -
Dutasteride After Failure of Finasteride In the Management of Symptomatic Prostatic Enlargement/Hypertrophy (BPE/H)
|
N/A | |
Completed |
NCT00029822 -
Clinical Trial in Males With BPH (Enlarged Prostate)
|
Phase 3 | |
Completed |
NCT05308017 -
Wolf 24 F vs. Storz 28 F Laser Sheath Size for HoLEP
|
N/A | |
Completed |
NCT00663858 -
Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
|
Phase 3 | |
Completed |
NCT00670306 -
Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)
|
Phase 3 | |
Terminated |
NCT00449150 -
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
|
Phase 3 | |
Completed |
NCT00037141 -
Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate)
|
Phase 1/Phase 2 | |
Suspended |
NCT02533687 -
Comparison of Different Energy Sources During TUR-P
|
N/A | |
Completed |
NCT00427219 -
The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate
|
Phase 2 | |
Completed |
NCT04781049 -
Transperineal Laser Ablation vs Transurethral Resection for Benign Prostatic Obstruction: A Randomized Clinical Trial
|
N/A | |
Completed |
NCT02051036 -
Moxibustion as an Adjuvant for Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms: a Pilot Study
|
N/A | |
Completed |
NCT00634608 -
Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow
|
N/A | |
Completed |
NCT02401581 -
Feasibility Study of Photovaporisation of Prostate With a Limitated Length of Catheterization of 3 Hours
|
N/A |